Tue, August 8, 2023
Mon, August 7, 2023
Sun, August 6, 2023
Fri, August 4, 2023

Matt Miksic Maintained (TNDM) at Buy with Decreased Target to $62 on, Aug 7th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-62-on-aug-7th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matt Miksic of Barclays, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Buy with Decreased Target from $71 to $62 on, Aug 7th, 2023.

Matt has made no other calls on TNDM in the last 4 months.



There are 7 other peers that have a rating on TNDM. Out of the 7 peers that are also analyzing TNDM, 4 agree with Matt's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jeff Johnson of "Baird" Maintained at Hold with Decreased Target to $33 on, Friday, August 4th, 2023
  • Joanne Wuensch of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $33 on, Friday, August 4th, 2023
  • Larry Biegelsen of "Wells Fargo" Maintained at Hold with Decreased Target to $30 on, Friday, August 4th, 2023
  • Jayson Bedford of "Raymond James" Downgraded from Buy to Hold on, Monday, April 24th, 2023


These are the ratings of the 3 analyists that currently disagree with Matt


  • Joshua Jennings of "TD Cowen" Maintained at Buy with Decreased Target to $34 on, Friday, August 4th, 2023
  • Alexander Nowak of "Craig-Hallum" Maintained at Strong Buy with Decreased Target to $50 on, Tuesday, June 13th, 2023
  • Travis Steed of "B of A Securities" Downgraded from Hold to Sell and Decreased Target to $33 on, Friday, May 5th, 2023

Publication Contributing Sources